Hemispherx: FDA decision on Ampligen won't come until fall

07/23/2009 | American City Business Journals

The FDA might take until fall to decide on Hemispherx BioPharma's application for Ampligen, an experimental treatment for chronic fatigue syndrome, because of staffing problems, said Dr. William Carter, the company's president and CEO. The biotech firm, which Carter said has been communicating with the FDA since May, is in discussions with potential marketing partners while the agency reviews the product.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX